350 Avsnitt

  1. 326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI

    Publicerades: 2024-10-10
  2. 325: Biden's health care AI czar, a new obesity company, and its dealmaking CEO

    Publicerades: 2024-10-03
  3. From Tradeoffs: Race to the Bottom

    Publicerades: 2024-09-28
  4. 324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug

    Publicerades: 2024-09-26
  5. 323: Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates

    Publicerades: 2024-09-19
  6. 322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids

    Publicerades: 2024-09-12
  7. 321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target

    Publicerades: 2024-09-05
  8. 320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy

    Publicerades: 2024-08-29
  9. From "Say More": What Happens When AI Decides Your Medical Coverage

    Publicerades: 2024-08-23
  10. 319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides

    Publicerades: 2024-08-22
  11. 318: Drug pricing drops & psychedelics under fire

    Publicerades: 2024-08-15
  12. 317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision

    Publicerades: 2024-08-08
  13. 316: The long journey to make malaria vaccines, and Sarepta's ties with patient advocates

    Publicerades: 2024-08-01
  14. 315: UnitedHealth's doctor empire, an FDA departure, and Viking's obesity moves

    Publicerades: 2024-07-25
  15. 314: JD Vance's biotech ties, Cassava resignations, and insulin shortages

    Publicerades: 2024-07-18
  16. 313: Biotech layoffs, founder-focused VC, & a big pharma exit

    Publicerades: 2024-07-11
  17. 312: Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate

    Publicerades: 2024-06-27
  18. 311: Fauci's memoir, Alnylam's tenuous trial, and a mid-year review

    Publicerades: 2024-06-20
  19. 310: Duchenne gene therapy setback, Alzheimer's drug endorsement & why a STAT reporter buys weed (for journalism)

    Publicerades: 2024-06-13
  20. 309: Psychedelics at the FDA, ASCO recap, & MorphoSys update

    Publicerades: 2024-06-06

2 / 18

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Visit the podcast's native language site